Role of IL-1-Mediated Inflammation in Tumor Angiogenesis

  • Elena Voronov
  • Yaron Carmi
  • Ron N. Apte
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 601)


Angiogenesis, or generation of new blood vessels from pre-existing vessels, is an integral part of many physiological or pathological processes, including tumor growth. Physiological angiogenesis is a complex process controlled by different proangiogenic as well as antiangiogenic factors. For angiogenic induction, the balance between these pro- and anti-angiogenic factors in the microenvironment has to shift in favor of proangiogenic factors, either by upregulation of these pro-angiogenic factors or by downregulation of angiogenic inhibitors. Proinflammatory cytokines, such as IL-1 and TNFα , were found to be major pro-angiogenic stimuli of both physiological and pathological angiogenesis. The IL-1 family consists of pleiotropic proinflammatory and immunoregulatory cytokines, namely, IL-1α and IL-1β , and one antagonistic protein, the IL-1 receptor antagonist (IL-1Ra), which binds to IL-1 receptors without transmitting an activation signal and represents a physiological inhibitor of preformed IL-1. Previously, we described an important role for microenvironment IL-1, mainly IL-1β , in tumor angiogenesis. In this chapter, we analyze the role of microenvironment host- and tumor cell-derived IL-1 on angiogenesis and the role of inflammation in pathological angiogenesis.


Vascular Endothelial Growth Factor Endothelial Progenitor Cell Proangiogenic Factor Antiangiogenic Factor Immature Myeloid Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Apte, R.N., Dotan, S., Elkabets, M., White, M.R., Reich, E., Carmi, Y., Song, X., Dvorkin, T., Krelin, Y. and Voronov, E. (2006a) The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 25, 387–408.CrossRefPubMedGoogle Scholar
  2. Apte, R.N., Krelin, Y., Song, X., Dotan, S., Recih, E., Elkabets, M., Carmi, Y., Dvorkin, T., White, R.M., Gayvoronsky, L., Segal, S. and Voronov, E. (2006b) Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. Eur. J. Cancer 42, 751–759.CrossRefPubMedGoogle Scholar
  3. Apte, R.N. and Voronov, E. (2002) Interleukin-1-a major pleiotropic cytokine in tumor-host interactions. Semin. Cancer Biol. 12, 277–290.CrossRefPubMedGoogle Scholar
  4. Asahara, T. and Kawamoto, A. (2004) Endothelial progenitor cells for postnatal vasculogenesis. Am. J. Physiol. Cell Physiol. 287, C572–579.CrossRefPubMedGoogle Scholar
  5. Balkwill, F. (2002) Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 13, 135–141.CrossRefPubMedGoogle Scholar
  6. Bar, D., Apte, R.N., Voronov, E., Dinarello, C.A. and Cohen, S. (2004) A continuous delivery system of IL-1Ra reduces angiogenesis and inhibits tumor development. FASEB J. 18, 161–163.PubMedGoogle Scholar
  7. Ben-Av, P., Crofford, L.J., Wilder, R.L. and Hla, T. (1995) Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett. 372, 83–87.CrossRefPubMedGoogle Scholar
  8. Carmeliet, P. (2003) Angiogenesis in health and disease. Nat. Med. 9, 653–660.CrossRefPubMedGoogle Scholar
  9. Carmeliet, P. and Jain, R.K. (2000) Angiogenesis in cancer and other diseases. Nature 407, 249–257.CrossRefPubMedGoogle Scholar
  10. Dinarello, C.A. (1996) Biologic basis for interleukin-1 in disease. Blood 87, 2095–2147.PubMedGoogle Scholar
  11. El Awad, B., Kreft, B., Wolber, E.M., Hellwig-Burgel, T., Metzen, E., Fandrey, J. and Jelkmann, W. (2000) Hypoxia and interleukin-1beta stimulate vascular endothelial growth factor production in human proximal tubular cells. Kidney Int. 58, 43–50.CrossRefPubMedGoogle Scholar
  12. Elaraj, D.M., Weinreich, D.M., Varghese, S., Puhlmann, M., Hewitt, S.M., Carroll, N.M., Feldman, E.D., Turner, E.M. and Alexander, H.R. (2006) The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin. Cancer Res. 12, 1088–1096.CrossRefPubMedGoogle Scholar
  13. Fiedler, U. and Augustin, H.G. (2006) Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol. 27, 552–558.CrossRefPubMedGoogle Scholar
  14. Folkman, J. (2003) Fundamental concepts of the angiogenic process. Curr. Mol. Med. 3, 643–651.CrossRefPubMedGoogle Scholar
  15. Folkman, J. and D’Amore, P.A. (1996) Blood vessel formation: what is its molecular basis? Cell 87, 1153–1155.CrossRefPubMedGoogle Scholar
  16. Hanahan, D. and Folkman, J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353–364.CrossRefPubMedGoogle Scholar
  17. Ishikawa, M. and Asahara, T. (2004) Endothelial progenitor cell culture for vascular regeneration. Stem Cells Dev. 13, 344–349.CrossRefPubMedGoogle Scholar
  18. Jung, Y.D., Liu, W., Reinmuth, N., Ahmad, S.A., Fan, F., Gallick, G.E. and Ellis, L.M. (2001) Vascular endothelial growth factor is upregulated by interleukin-1 beta in human vascular smooth muscle cells via the P38 mitogen-activated protein kinase pathway. Angiogenesis 4, 155–162.CrossRefPubMedGoogle Scholar
  19. Krelin, Y., Voronov, E., Dotan, S., Elkabets, M., Reich, E., Fogel, M., Huszar, M., Iwakura, Y., Segal, S., Dinarello, C.A. and Apte, R.N. (2007) Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res. 67, 1062–1071.CrossRefPubMedGoogle Scholar
  20. Mantovani, A. and Dejana, E. (1989) Cytokines as communication signals between leukocytes and endothelial cells. Immunol. Today 10, 370–375.CrossRefPubMedGoogle Scholar
  21. Moldovan, N. I. and Asahara, T. (2003) Role of blood mononuclear cells in recanalization and vascularization of thrombi: past, present, and future. Trends Cardiovasc. Med. 13, 265–269.CrossRefPubMedGoogle Scholar
  22. Murayama, T., Tepper, O. M., Silver, M., Ma, H., Losordo, D.W., Isner, J.M., Asahara, T. and Kalka, C. (2002) Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor-induced neovascularization in vivo. Exp. Hematol. 30, 967–972.CrossRefPubMedGoogle Scholar
  23. Rafii, S., Lyden, D., Benezra, R., Hattori, K. and Heissig, B. (2002) Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer 2, 826–835.Google Scholar
  24. Song, X., Krelin, Y., Dvorkin, T., Bjorkdahl, O., Segal, S., Dinarello, C.A., Voronov, E. and Apte, R.N. (2005) CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1β -secreting cells. J. Immunol. 175, 8200–8208.PubMedGoogle Scholar
  25. Song, X., Voronov, E., Dvorkin, T., Fima, E., Cagnano, E., Benharroch, D., Shendler, Y., Bjorkdahl, O., Segal, S., Dinarello, C.A. and Apte, R.N. (2003) Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness. J. Immunol. 171, 6448–6456.PubMedGoogle Scholar
  26. Voronov, E., Shouval, D.S., Krelin, Y., Cagnano, E., Benharroch, D., Iwakura, Y., Dinarello, C.A. and Apte, R.N. (2003) IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl. Acad. Sci. USA 100, 2645–2650.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.The Shraga Segal Department of Microbiology and Immunology, Faculty of Health Sciences and Cancer Research CenterBen-Gurion University of the NegevBeer-ShevaIsrael

Personalised recommendations